Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Summary

This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.

Questions topics-

- Further Phase I data required for Roche's capsid inhibitor RO7049389

- Replicor's US trial plans and transition from IV to subcutaneous REP 2139

- Efficacy of Spring Bank's inarigivir at 100mg in the Phase II ACHIEVE trial

- Expected role for inarigivir in HBV

- Efficacy of Arbutus's Q2W IV ARB-1467

- ARB-1467, TDF + Peg-IFN trial design, potential for functional cure, & regimen acceptability

- Future development of Arbutus's next-generation RNAi therapeutic AB-729For internal use only

Key Highlights

- Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ-6379 & ABI-H0731, with most concluding that Phase I data is insufficien

- KOLs agree Replicor is making positive steps towards REP 2139's development, but similar efficacy & safety must be demonstrated in the US trials and for the SC formulation

- Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our HBV key opinion leaders (KOLs).

In total, we conducted interviews with 10 KOLs-

- 5 Europe-based & 5 N. America-based

- Interviews performed during Sept 2018

KOL data is analyzed to produce-

- Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "recent & upcoming data for key HBV pipeline agents"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of HBV

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

HBV, capsid inhibitor, functional cure, inarigivir


Companies

Roche

Replicor

Spring Bank

Arbutus